Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer

Oppenheimer lowered the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $32 and keeps an Outperform rating on the shares following quarterly results. Oppenheimer says it is “getting a bit tired” of the myopic argument that the CLL market is a zero-sum game – with BeOne beating Nurix to the punch. By the firm’s estimates, NX-5948 is 6-12 months behind BeOne, but has advantages in safety and efficacy that can be exploited.